. The genetic changes that underlie Wilms tumour are diverse and are driven by an array of ~40 cancer genes (Table 1) . Such diversity is particularly surprising given the monotonous driver landscape of other childhood tumours, including renal tumours such as clear cell sarcoma of the kidney or congenital mesoblastic nephroma. The median somatic mutation rate is far lower in Wilms tumour (0.17 per million bases (Mb)) than in adult papillary and clear cell renal cell carcinoma (1-10 per Mb) 3, 4 . Early knowledge of Wilms tumour-related genes was mainly derived from analyses of patients with Wilms tumour predisposition syndromes, identifying central roles in tumorigenesis for the Wilms tumour 1 (WT1) gene, the WNT pathway and insulin-like growth factor (IGF) signalling [5] [6] [7] . Large-scale genetic studies have now interrogated both the constitutional and somatic bases of Wilms tumour. Whole-exome sequencing has identified recurrent and unique mutations in microRNA processing genes (miRNAPGs) and in the transcription factor homeobox genes SIX1 and SIX2 (refs 8-11 ). In 2017, a mixed whole-genome and whole-exome sequencing study of 117 Wilms tumours identified novel mutations in genes encoding proteins involved in histone modification during nephrogenesis (BCOR and MAP3K4), proteins that interact with N-MYC proto-oncogene protein (MYCN; that is, NONO and MAX) and proteins that act as transcriptional co-repressors (such as BCORL1), among others 12 . This study identified germline mutations in cancer risk genes (REST, CHEK2 and PALB2) in children with non-syndromic Wilms tumour.
In this Review, we provide an overview of the genetic landscape that underpins Wilms tumour. We begin with the epidemiology, focusing on the narrow developmental window of Wilms tumour and the genetic risk factors that underlie the observed differences in incidence worldwide. We then highlight the main clinical challenges that are posed by Wilms tumour, concentrating on the genetic basis of subgroups with poor prognosis, before reviewing findings emerging from high-throughput sequencing studies of the Wilms tumour genome in the context of renal organogenesis. Classical Wilms tumour-related genes are also briefly considered. Finally, we discuss how precision medicine guided by genomic information might lead to new therapeutic approaches and improved survival of children with Wilms tumour.
Epidemiology
In almost 90% of cases, Wilms tumour is a sporadic event occurring in one kidney 1 . The majority of tumours (95%) are diagnosed in children under 10 years of age 1, 13 . Bilateral and multifocal tumours, or Wilms tumour on a
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background of a cancer predisposition syndrome, tend to present at an earlier age (median age of diagnosis of 2 years) than sporadic Wilms tumour (median age of diagnosis of 3 years) 13 . The former group includes children with WT1-associated congenital malformation syndromes and other urogenital malformation anomalies 14 . Tumours that are associated with asymmetric overgrowth tend to present at the more typical median age of 3 years, although this depends on genetic subtype 15 . Age at diagnosis also varies between ethnicities. For example, in the United States, black children are diagnosed later than white or Asian children 13 . The reason for this difference is unknown.
The highest incidence of Wilms tumour is found in children of African descent (10 cases per million) and the lowest in Asian populations (3 cases per million). In white children, the incidence is 6-9 cases per million 1, 16 . Among children born in the United States, Hispanic children have a lower incidence of Wilms tumour than white children, and this risk varies within the population depending on maternal birthplace 17, 18 . Several genome-wide association studies (GWAS) in Chinese, UK and US populations, but not in cohorts of mixed ethnicity, have identified polymorphisms that confer Wilms tumour susceptibility, including polymorphisms in HACE1, BARD1, 2p24 and 11q14 (refs 19-21 ).
Loss of imprinting at 11p15 is more frequently identified in white children than in Asian children born in Japan or in the United States 22 . Conversely, analysis of bilateral tumours from Japanese children revealed a far higher incidence of constitutional WT1 anomalies than identified in white children with bilateral tumours 23 . The histological subtype of Wilms tumour also seems to vary by ethnicity. Registration of high-risk anaplastic histology was only 4.9% in the Japan Wilms Tumour Study Group compared with 10.8% in the American National Wilms Tumour Study 5 (NWTS-5) 24 .
Management and risk stratification
Two different strategies for managing children diagnosed with a renal tumour exist. In Europe, the majority of children older than 6 months receive preoperative chemotherapy in line with the Société Internationale d'Oncologie Pédiatrique Renal Tumours Study Group (SIOP-RTSG) protocols 25 . By contrast, in North America, most children undergo immediate nephrectomy as per the National Wilms Tumour Study/Children's Oncology Group (COG) protocol 26 . The 2-year event-free survival and overall survival for all children with Wilms tumour treated in the large-scale European SIOP-2001 trial were 87% and 93%, respectively, with similar results reported in COG trials 27, 28 . Both SIOP-RTSG and COG use stage of disease and histological subtype to stratify postoperative therapy. SIOP classifies tumours as low risk (completely necrotic), intermediate risk (epithelial, stromal, regressive or mixed subtype, including focal anaplasia) or high risk (blastemal type and diffuse anaplasia) 25 ( fig. 1 ). The blastemal subtype can be identified only by the percentage of blastema remaining following preoperative chemotherapy in a non-regressive subtype tumour. By contrast, COG characterizes treatment-naive histology as favourable (that is, non-anaplastic) or unfavourable (that is, focal and diffuse anaplasia) 29 .
Since 2005, COG has included a molecular marker in risk stratification, treating children whose tumours have loss of heterozygosity (LOH) for alleles spanning chromosomes 1p and 16q with more intensive chemotherapy 30, 31 . Although the mechanism of oncogenesis in tumours with combined 1p/16q LOH remains uncertain, this biomarker is significantly associated with risk of relapse and death 31 . Uniquely, COG stratification defines a group of children with very low-risk tumours that do not require adjuvant cytotoxic treatment, that is, tumours in children younger than 2 years old with stage I favourable histo logy and tumour weight <550 g (ref.
32
). In this group, only LOH at 11p15 is reproducibly associated with disease recurrence 32, 33 . It is evident that the current risk stratification systems for Wilms tumour are incomplete. In particular, large-scale sequencing studies that characterize tumours from patients who experienced relapse, and were originally stratified as having low-risk or intermediate-risk disease, are very much needed. The findings of such studies would address the question of whether recurrent tumours are genetically distinct from primary Wilms tumours 34 .
clinical challenges Overall, the treatment of Wilms tumour can be considered a success story, with clear management pathways delineated for most children. However, the treatment of children with bilateral, relapsed and high-risk tumours remains challenging. Improved understanding of oncogenesis to enable refinements in risk stratification and the development of novel agents is a priority for these groups. A further aim is to reduce the burden of treatment by identifying low-risk patients in whom reduction of therapy is feasible while maintaining excellent survival 35 . The impact of genetic risk on late adverse treatment effects, including heart and kidney failure, subfertility and second cancers, is beginning to be understood as a result of GWAS that have identified polymorphisms that are associated with increased drug toxicity 36 .
Key points
• Wilms tumour is the most common childhood renal malignancy; the incidence differs between ethnicities worldwide.
• The treatment of Wilms tumour can be considered a success story, but the management of patients with high-risk histology, bilateral tumours and/or relapsed disease remains challenging.
• The genetic changes that underpin Wilms tumour are diverse and involve ~40 cancer genes; this diversity is particularly surprising given the monotonous driver landscape of other childhood renal tumours.
• Genome sequencing of Wilms tumours has identified cancer genes that harbour likely driver mutations, including epigenetic remodellers, microRNA processing genes and the transcription factors SIX1 and SIX2.
• many Wilms tumour-related genes have pivotal roles in the developing kidney, supporting the hypothesis that Wilms tumour development is coupled to aberrant nephrogenesis.
• Targeting somatic variants with prognostic significance, as well as the fetal renal transcriptome, may provide promising therapeutic avenues for patients with relapsed or refractory disease.
Knowledge of genetic risk factors could be used to identify survivors of childhood cancers who could benefit from protective interventions and/or longer follow-up.
Relapse. Relapse in Wilms tumour occurs in approximately 15% of children and normally occurs within 2 years of diagnosis 37, 38 . Overall survival varies between 10% and 70% depending on the initial treatment, relapse site and histology [39] [40] [41] [42] . In SIOP-2001, the relapse rates among 3,559 children were 26% in the high-risk, 11% in the intermediate-risk and 5% in the low-risk groups 27 . Relapse occurs in up to 15% of very-low-risk patients (as defined by COG) who are treated with surgery alone 43 . Current surveillance imaging captures up to 70% of relapses, and prognostic factors for recurrence are not fully understood 38 . Molecular biomarkers with clinicopathological importance are urgently needed to identify high-risk tumours. Current candidates include 1q gain, mutant TP53 and variant MYCN. For all histological risk groups, gain of 1q consistently predicts poorer event-free survival and a reduction in overall survival in the COG cohort [44] [45] [46] . Although this molecular biomarker is the most promising candidate for risk stratification, affecting 28% of all Wilms tumours, the biological mechanism underlying this risk is unknown. 
www.nature.com/nrneph
Bilateral tumours. Bilateral tumours (stage V disease) in which Wilms tumour and/or persistent abnormal embryonic tissue, known as nephrogenic rests, affect both kidneys are found in 5-8% of cases 47 . The mechanism of transformation from nephrogenic rests to Wilms tumour, or indeed whether nephrogenic rests are truly Wilms tumour precursor lesions, is unknown. Such questions lend themselves to phylogenetic analyses of mutation catalogues. A comparison of nephrogenic rests with embryonic kidneys identified hypermethylation of genes involved in nephrogenesis, with further methylation of these loci in the Wilms tumours 48 . Bilateral tumours often arise in the context of a cancer predisposition syndrome. For example, in 545 cases of bilateral Wilms tumour, bona fide pathogenic germline variants were found in 22% 49 . The most common predisposition variants are mutation of WT1 and 11p15 loss of imprinting 49 . The management of bilateral tumours remains challenging, particularly in the context of WT1 mutation syndromes that are associated with inherent predisposition to renal failure.
Anaplasia. Diffuse anaplastic Wilms tumour (DAWT) is associated with poorer outcomes than other histological subtypes 50 . Somatic mutations in TP53 are found in up to 60% of anaplastic tumours [51] [52] [53] . These mutations are limited to the anaplastic regions and are rarely seen in other histological subtypes 51 . However, an analysis of fatal tumours found mutant TP53 in 26% of non-anaplastic cases 54 . It is conceivable that anaplasia may have been missed in some of these cases or that TP53 mutations can occur in the absence of anaplasia. Another possible interpretation is that variant TP53 may be a clonal event preceding the development of anaplasia.
In advanced-stage DAWT, tumours with TP53 mutations are associated with an increased risk of relapse and mortality in comparison with those with wild-type
53 ). Despite this association, genetic testing of tumours is not routinely undertaken, and all patients with DAWT are stratified to receive intensive postoperative treatment. Earlier identification of DAWT, for example, through detection of mutant TP53 in circulating tumour DNA at diagnosis, would enable intensification of preoperative chemotherapy in patients treated according to the SIOP protocol 55 .
Wilms tumorigenesis and nephrogenesis
Accumulating evidence suggests that Wilms tumour arises from aberrant fetal nephrogenesis. The definitive kidney anlage, the metanephros, forms at around the fifth week of gestation from the intermediate mesoderm through a sequence of reciprocal and complex tissue interactions involving the ureteric bud, a caudal outpouching of the Wolffian duct and the metanephric mesenchyme 56 . As the ureteric bud invades the metanephric blastema, the cells condense and undergo mesenchymal-to-epithelial transition (MET), leading to early tubule formation. These early tubules will eventually become the glomerular podocytes, proximal and distal tubules and loop of Henle, whereas the ureteric bud is induced to branch and forms the collecting duct system.
In Wilms tumour, the differentiation arrest of renal progenitor cells is incomplete, and all three lineages of the developing kidney (blastema, epithelia and stroma) can be identified in classic triphasic Wilms tumour histology 57 . A microarray analysis of over 300 Wilms tumours reported that the gene expression forms a triangular continuum with vertices corresponding to blastemal, stromal and epithelial cell types, which correlate with cap mesenchyme, uninduced metanephric mesenchyme and renal epithelium, respectively 58 . An analysis of Wilms tumour patient-derived xenografts that were enriched for blastema showed high expression of renal progenitor genes (SIX1, SALL1, WT1, PAX2, 
Mesenchymal-to-epithelial transition
(MeT). The alteration of a cell phenotype from a mesenchymal state to epithelia.
NATuRe RevIeWS | NePhRoloGy LIM1, EYA1 and FOXC1), paternally derived genes that characterize the early metanephric mesenchyme (IGF2, DLK1, PEG3, PEG10 and NNAT (also known as PEG5)) and genes that maintain self-renewal capacity (MEIS1 and EZH2) 59 . The mRNA expression of a Polycomb group protein, histone-lysine N-methyltransferase EZH2, is downregulated during nephrogenesis and upregulated in tumorigenesis 60 . This protein is thought to control the methylation status of renal stem cells via hypomethylation of WT1, PAX2 and SIX2 (ref. 60 ).
Of interest, hypermethylation and silencing of SIX2 were seen in late Wilms tumour xenografts, leading to loss of renal differentiation 60 . Single-cell analysis of these tumours identified a unique cell subpopulation (SERPINE1 + SIX2 − ) corresponding to the uninduced mesenchyme, suggesting that as tumour development progresses, malignant stem cells may be transformed away from the renal lineage 60, 61 . Gene expression profiles that segregate Wilms tumour into clinically relevant groups, coupled to different stages of renal development, suggest that initiating events may differ throughout nephrogenesis 62 . The largest group involved biallelic expression of IGF2 and expression of genes corresponding to the metanephric mesenchyme, with the presence of both intralobar nephrogenic rests (ILNRs) and perilobar nephrogenic rests (PLNRs). Another group matched to the very early metanephric mesenchyme, the intermediate mesoderm, with triphasic histology and a high incidence of both WT1 mutations and WNT pathway activation. A third subset of tumours shared similar pathogenic mutations (WT1 and CTNNB1) but with an expression profile corresponding to the metanephric mesenchyme. Finally, a novel subset was identified involving epithelial tumours without nephrogenic rests that were heterozygous for 1p/16q, with wild-type WT1 and gene expression corresponding to the post-induction metanephric mesenchyme. These tumours occurred in infants, none of whom relapsed.
Two markers of renal progenitor cells, NCAM1 (also known as CD56) and CD133 (also known as prominin 1), map the sequential stages of MET in nephrogenesis and in Wilms tumorigenesis 63 . Renal stem cells in fetal kidneys and undifferentiated blastema in Wilms tumour are NCAM1 + CD133 − , whereas immature epithelia are NCAM1 + CD133 + , and mature epithelia are NCAM1 − CD133
+ (ref. 63 ). Hence, in both normal and abnormal nephrogenesis, NCAM1 expression is lost during MET, whereas CD133 expression increases with epithelial differentiation.
Within blastema, cell subpopulations expressing NCAM1 and ALDH1 are thought to be Wilms tumour cancer stem cells (CSCs), owing to their ability to recapitulate all the cell lineages that are found within Wilms tumour when transplanted into mice 64 . However, the cellular plasticity of these CSCs, namely, their ability to undergo MET and also to de-differentiate into mesenchymal progenitor cells, suggests that they are not the earliest renal stem cells 65 . Wilms tumour CSC-derived xenografts had high expression of phosphorylated PI3K and PKB, as well as reduced expression of the miR-200 family, compared with fetal kidneys 64 .
The miR-200 family has a crucial role in MET in the developing kidney, and its downregulation is thought to lead to failure of this process 66 . Activation of the PI3K-PKB pathway has also been observed in Wilms tumour and has been shown to have a role in tumour growth and metastasis 67 . The increasing number of Wilms tumour-related genes with pivotal roles in the developing kidney ( fig. 2) supports the hypothesis that Wilms tumour is inextricably linked to stalled renal organogenesis. Moreover, in 2018, single-cell transcriptomes of Wilms tumour were shown to match with fetal developing nephron populations 68 . As nephrogenesis is completed before birth, targeting the fetal renal transcriptome might be a fruitful strategy for treating childhood Wilms tumours.
germline mutations
In up to 15% of cases, Wilms tumour occurs on a background of a predisposition syndrome or germline mutation in cancer risk genes 69, 70 (Table 2 ).
Syndromic and familial Wilms tumour.
The first gene to be implicated in Wilms tumorigenesis was WT1 at 11p13 (refs 71,72 ). This gene encodes a zinc-finger DNA-binding transcription factor that is non-redundant for urogenital development and glomerular function 73, 74 . WT1 is expressed in the metanephric and condensing mesenchymes. Its loss results in a spectrum from complete renal agenesis to disrupted differentiation of the progenitor cells belonging to the metanephric mesenchyme, depending on the stage of nephrogenesis at which the gene is lost [74] [75] [76] . Over 100 genes seem to be regulated by the two major isoforms of WT1, many of which are required for renal development and are themselves mutated in Wilms tumour 77 .
No recurrent loci for somatic WT1 mutations in Wilms tumour exist. Mechanisms of WT1 inactivation include mutations that affect the DNA-binding domain and those that produce truncated proteins that lack this domain completely 6 . The association of WT1 with ILNRs suggests that somatic WT1 loss may be an early event in tumorigenesis 78 . The constellation of urogenital malformation, renal failure and Wilms tumour susceptibility occurs in several syndromes, which all have constitutional abnormalities in the WT1 gene. The most common of these syndromes is Wilms tumour, aniridia, genitourinary tract abnormalities and a range of developmental delays (WAGR) syndrome. This syndrome is caused by microdeletion of 11p13, including the WT1 locus and the adjacent gene PAX6, mutation of which causes aniridia 79 . The risk of Wilms tumour development in children with WAGR syndrome is around 50%, and these children present earlier and have a higher incidence of bilateral Wilms tumours than children with non-syndromic Wilms tumours 80 . Similarly, bilateral disease occurs in 20% of children with Denys-Drash syndrome (DDS), which is characterized by ambiguous genitalia and nephropathy secondary to diffuse mesangial sclerosis 81 . Missense mutations in the DNA-binding domain of WT1 underlie DDS 82 . Mutations that alter WT1 splicing
Aniridia
The partial or complete absence of the iris.
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cause Frasier syndrome, which is phenotypically similar to DDS but with focal segmental glomerulosclerosis and a predisposition to gonadoblastoma 83 . A second Wilms tumour locus was identified at 11p15 (ref 84 ). Abnormal methylation at 11p15 is the most common genomic change found in Wilms tumour, is uniformly present in multiple samples from individual tumours and is found in PLNRs 85, 86 . Multiple germline epigenetic and genetic changes at 11p15 are responsible for the overgrowth syndrome BeckwithWiedemann syndrome (BWS), which is associated with increased risk of embryonal tumours including Wilms tumour, neuroblastoma, hepatoblastoma and rhabdomyosarcoma 87 . Wilms tumour develops in 20% of cases of BWS, with the highest risk associated with uniparental disomy or H19 hypermethylation 88 , resulting in biallelic expression of IGF2 and overactivation of the IGF signalling pathway 89 . However, the most common epigenetic subgroup of BWS, characterized by hypomethylation of KvDMR1, does not increase the risk of Wilms tumour.
Another generalized overgrowth syndrome with susceptibility to Wilms tumour is the X-linked SimpsonGolabi-Behmel syndrome. In this syndrome, mutations occur in the GPC3 gene, which encodes an extracellular proteoglycan that has a role in promoting WNT signalling 90 . Disruption of miRNA biogenesis through germline mutations in DIS3L2 is the basis of Perlman syndrome 91 . This rare overgrowth syndrome is also associated with susceptibility to Wilms tumours, of which more than half are bilateral. Susceptibility to Wilms tumour also occurs in several other tumour predisposition syndromes including Li-Fraumeni syndrome (TP53) and Fanconi anaemia (BRCA2 and PALB2) 14, 92 . Familial Wilms tumour pedigrees account for 1-2% of cases and are known to involve several different heritable mutations 93 . Mutations in the miRNAPG DICER1 underlie the pleiotropic cancer susceptibility DICER1 syndrome and have been identified as a cause of familial Wilms tumour 94 . Constitutional mutations in CTR9 have also been found in several families with Wilms tumour 95, 96 . CTR9 forms part of the PAF1 complex, which has a role in maintaining embryonic stem cell pluripotency 97 . Two further predisposition loci at 17q21(FWT1) and 19q13 (FWT2) were identified by genetic linkage studies of families affected by Wilms tumour 98, 99 . Although the genes have yet to be characterized, an analysis of siblings with Wilms tumour identified loss of function of the transcriptional co-repressor TRIM28 (also known as TIF1-β), which is located at FWT2. (ref. 100 ).
TRIM28 is highly expressed in the early ureteric bud and metanephric mesenchyme, and knockdown of the
Ureteric bud invasion Formation of cap mesenchyme and branching of the ureteric bud
Mesenchymal-to-epithelial transition . First, the ureteric bud, a caudal outpouching of the Wolffian duct, invades the metanephric mesenchyme. The cells of the metanephric mesenchyme then condense into cap mesenchyme, while the ureteric bud is itself induced to branch. Mesenchymal-to-epithelial transition occurs to form primitive vesicles. Transition of the mesenchymal progenitor population to epithelial cells is regulated by a complex network of genes that control a delicate balance between self-renewal and differentiation. Mutations or variants in many of these genes are associated with the development of Wilms tumour. A key regulator of the entire process is WT1, the expression of which increases throughout development from the metanephric mesenchyme to the cap mesenchyme and the primitive vesicles . Mesenchymalto-epithelial transition is mediated by the WNT pathway , which is under direct control of WT1 via WNT4 (ref.
152
). WNT4 is also regulated by β-catenin (which is encoded by CTNNB1) and SIX2 (ref.
153
). Activity of SIX2 maintains the mesenchyme progenitor population in an undifferentiated state 133 . In the metanephric mesenchyme, WT1, SIX2 and CTNNB1 work together to activate the FGFR signalling pathway 154 . FGFR1 is necessary for nephron progenitor cell survival, branching of ureteric buds and elongation of primitive vesicles into comma and s-shaped bodies that eventually become the mature nephron 155 . CHD4 is required to maintain the cap mesenchyme progenitor population as is the transcriptional repressor SALL1, which is also controlled by WT1 (ref. 
Uniparental disomy
a chromosomal disorder whereby the chromosome pair is inherited from one parent.
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Non-syndromic Wilms tumour. Germline mutations occur in around 10% of patients with non-syndromic Wilms tumour 12 . Putative Wilms tumour predisposition genes include REST, CHEK2, EP300, PALB2 and ARID1A 12, 102 . CHEK2 is a tumour suppressor gene that contributes to hereditary breast cancer; germline mutations in this gene have also been identified in high-grade paediatric brain tumours and adult renal cell carcinoma [103] [104] [105] . Germline mutations in another breast cancer risk gene, PALB2, are preferentially associated with diffuse anaplastic Wilms tumour 12 . Biallelic mutations in PALB2 underlie Fanconi anaemia subtype FA-N and have also been identified in familial Wilms tumour 92 . Another candidate tumour suppressor gene with inactivating mutations that predispose to Wilms tumour is REST, which encodes a transcriptional repressor with a non-redundant role in embryogenesis 102 . Mutations in REST have been found in familial Wilms tumour pedigrees and also occur in several other cancers including neuroblastoma 102, 106 .
Somatic mutations
Until a few years ago, the only known somatic mutations in Wilms tumour were those involving WT1, LOH at 11p15, the WNT pathway (that is, AMER1 and CTNNB1), TP53 and MYCN. Of these genes, only mutations in TP53 and MYCN have clinicopathological associations.
The overwhelming majority of variants in CTNNB1 mutate serine 45, which is a functionally critical phosphorylation residue necessary for β-catenin degradation 107, 108 . Mutations in the YEATS domain of MLLT1 have also been identified in Wilms tumour and often occur alongside variant CTNNB1 (ref. 109 ). The YEATS domain binds directly to the PAF1 complex to promote transcriptional elongation during nephrogenesis 110 . As MLLT1 mutant tumours occur in very young children (median age at diagnosis of 12 months) and co-occur with ILNRs 102 , mutation of MLLT1 is likely to be an early event in tumorigenesis.
The application of unbiased tumour genome sequencing has identified additional cancer genes that harbour likely driver mutations in Wilms tumour. For example, whole-exome sequencing identified alterations in the epigenetic remodellers SMARCA4 and ARID1A, which are members of the BAF chromatin remodelling complex 111 . Variants in these genes are also found in clear cell renal cell carcinoma, medulloblastoma and atypical teratoid rhabdoid tumour [112] [113] [114] . MicroRNA biogenesis and the miRNAPGs DROSHA, DICER1, DGCR8, XPO5 and TARBP2 have also been implicated in Wilms tumour 8 . Wilms tumour-specific oncogenes that have been discovered include SIX1 and SIX2, which encode transcription factors with a non-redundant role in renal development 10, 11 . The roles of miRNAPG, SIX1 and SIX2 in nephrogenesis are discussed further below.
Whole-genome and whole-exome sequencing of 117 Wilms tumours added further candidates to the genetic landscape of this disease 12 . Wilms tumour-related cancer genes now include genes that are involved in histone modification during nephrogenesis (BCOR, MAP3K4, BRD7, CREBBP and HDAC4) and genes that mediate transcriptional repression (BCORL1). Alterations were also identified in ACTB (β-actin), which together with SMARCA4 and ARID1A forms the BAF chromatin remodelling complex. MAP3K4 has been shown to control CREBBP activity in trophoblast cells, with combined loss resulting in multipotency and epithelial-to-mesenchymal transition 115 . BCOR and the homologous BCORL1 are ubiquitously expressed and postulated to have tumour suppressor function, with both somatic truncating mutations and fusion transcripts identified in several haematological cancers including paediatric acute myeloid leukaemia [116] [117] [118] [119] . Internal tandem duplications of BCOR are the sole driver of tumorigenesis in the vast majority (>85%) of patients with clear cell sarcoma of the kidney 120 . Mutations in NONO and MAX, which encode proteins that interact with MYCN, have also been identified in Wilms tumour, and MAX expression seems to correlate with clinical outcome in neuroblastoma [121] [122] [123] . Mutations have also been identified in ASXL1, which encodes a Polycomb group protein. Such proteins are recruited by WT1, leading to downregulation of the expression of Pax2, which is a transcriptional regulator with a vital role in urogenital development 124 . Germline mutations in ASXL1 underlie some cases of Bohring-Opitz syndrome, with increased risk of bilateral Wilms tumour in these children 125 . Denys-Drash syndrome WT1 missense mutation 81 Perlman syndrome DIS3L2 mutation 91 Fanconi anaemia Biallelic BRCA2 or PALB2 mutation 92, 104 Mosaic variegated aneuploidy Biallelic BUB1B or TRIP13 mutation 159 
Moderate risk of Wilms tumour (5-20%)
Frasier syndrome WT1 intron 9 splice mutation 83 Beckwith-Wiedemann syndrome Uniparental disomy or H19 epimutation 88, 160 Simpson-Golabi-Behmel syndrome GPC3 mutation 90 
Low risk of Wilms tumour (<5%)
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In addition to their genetic diversity, Wilms tumours display intratumoural diversity 85 . Such micro-diversity was associated with higher histological risk, advanced stage and poorer outcome in a study of 44 Wilms tumours that had been exposed to chemotherapy as per the SIOP protocol 126 . Copy number variants (CNVs) are common, and the following are not uniformly spatially distributed throughout multiple samples of individual tumours: gain of 1q, gain of 2p24 (MYCN locus) and 17p13 loss (TP53) 12, 54, 85 . Loss of 17p13 is predominantly associated with anaplastic tumours, which display a characteristically unstable cancer genome with additional loss of 4q and 14q 127 . Gain of 2p24 (MYCN) is also associated with anaplasia and has been reported to occur as both a somatic and germline event 128 . Four patterns of clonal evolution underlying intratumoural heterogeneity that are common to Wilms tumour, neuroblastoma and rhabdomyosarcoma have been identified 34 . The most frequently observed pattern is subclonal variation across samples from the same tumour, followed by the coexistence of subclones across multiple spatially separated areas. Two rarer patterns include a clone with driver mutations that exhibits regional dominance and 'regional evolutionary explosion' , whereby multiple clones exist locally. Of these patterns, the only trajectory to correlate with a specific mutation is 'regional evolutionary explosion' occurring in tumours with anaplasia and TP53 inactivation. This evolution predicted relapse and death, independent of clinical risk stratification, in 54 patients with childhood cancers 34 
.
Mutations in microRNA processing genes. Mutations in miRNAPG, including DROSHA, DICER1, DGCR8, XPO5 and TARBP2, have been found in chemotherapy-naive Wilms tumours and in Wilms tumours exposed to neoadjuvant agents [8] [9] [10] [11] . The mutational hot spot in the metal-binding RNase IIIb domain of DROSHA (E1147K) seems to be unique to Wilms tumour, as it has not been found in other childhood or adult cancers. Recurrent mutations in the RNA-binding domains of DROSHA, DGCR8 and DICER1 variant tumours lead to impaired miRNA biogenesis [8] [9] [10] . Global downregulation of mature miRNAs, including the LET7 family, occurs in DROSHA mutants and results in failure of epithelial differentiation 8, 9 . Partial loss of mature miRNAs is seen in tumours with DICER1 variants 9 . Let7 miRNA processing is suppressed by the RNA-binding protein Lin28b, and overexpression of Lin28b during nephrogenesis leads to Wilms tumour formation in mice 129 . Copy number gain of LIN28B and loss of Let7 are seen in 25% and 46% of Wilms tumours, respectively, and cluster separately to miRNAPG variant tumours in terms of gene but not miRNA expression 12 . A reduction in expression of the miR-200 family, which is critical for MET, is also seen in association with miRNAPG mutations 10 . The precise role of DROSHA in nephrogenesis is unknown; however, DICER1 has been shown to be necessary for maintaining the viability of the progenitor stem cell pool in murine models 130 . Mutations in miRNAPG are associated with pre-therapy blastemal histology, PLNRs and aberrant imprinting at 11p15 (ref.
10
). The high frequency of loss of imprinting at 11p15 observed in tumours with combined miRNAPG and SIX or SIX2 alterations suggests multiple events are responsible for Wilms tumorigenesis in blastemal subtype tumours 11 . This combination, although infrequent, may be associated with both relapse and poor outcome. Reports regarding the prevalence of WT1 alterations in miRNAPG-mutant tumours are inconsistent, with some studies showing that the two mutations occur in a mutually exclusive fashion and others finding concordance 8, 9 . A surprising sex bias has been associated with mutations in DGCR8, with 88% of cases occurring in females 10, 11 .
Mutations in SIX1 and SIX2. The three studies that have identified mutations in SIX1 and SIX2 in patients with Wilms tumour all found a recurrent Q177R mutation in the DNA-binding homeodomain of these transcription factors, resulting in a glutamine-to-arginine substitution [10] [11] [12] . Recurrent hotspot mutations in SIX1 and SIX2 are unique to Wilms tumour. However, germline mutations in different loci within the homeobox of SIX1 occur in branchio-oto-renal syndrome, which is characterized by a spectrum of kidney abnormalities excluding Wilms tumour 131 . SIX1 and SIX2 are key regulators of nephrogenesis. Loss of SIX1 leads to mesenchymal apoptosis in SIX1-knockout mice 132 , whereas SIX2 activity maintains the mesenchyme progenitor population in an undifferentiated blastema state 133 . Expression of cell cycle genes is upregulated in SIX1-mutant and SIX2-mutant Wilms tumours. SIX2 overexpression in renal cell lines correlates with an increased percentage of cells in the S-phase 10, 11 . This cumulative evidence suggests that SIX1 and SIX2 have oncogenic function in a subset of tumours and drive proliferation of the metanephric mesenchyme. In Wilms tumour, SIX1 and SIX2 mutations are associated with the high-risk blastemal subtype defined by SIOP and with the presence of undifferentiated blastema in chemotherapy-naive samples 10, 11 . SIOP and COG data are inconsistent with regards to the prognostic importance of tumours that harbour both miRNAPG and SIX1 or SIX2 mutations, with only the COG data showing an association 10, 11 . Analysis of a larger subset of patients, followed up for relapse, is necessary to clarify this issue.
novel therapeutic targets
Although Wilms tumour is largely curable in the developed world, identifying novel therapeutics remains a priority for subgroups of children with a poor prognosis. Several promising avenues for therapy exist, particularly those that involve targeting somatic variants identified in patients with relapse and/or fatal tumours.
One potential candidate is MYCN, which is ubiquitously associated with poor outcome in many childhood cancers including Wilms tumour, neuroblastoma, medulloblastoma and rhabdomyosarcoma 7, 128, 134, 135 . MYCN was considered to be an 'undruggable' target before the advent of inhibitors of Aurora A kinase (AURKA), which block the interaction between AURKA and MYCN, enabling MYCN degradation 136 .
However, only 13% of Wilms tumours have variant MYCN or MYCN copy number gain 128 . In a phase II study of the AURKA inhibitor alisertib (Takeda), eight of ten patients with Wilms tumour had progressive disease during the trial, and only one patient demonstrated an overall response; however, MYCN status was not assessed in this study 137 . Given the association between MYCN and poor outcome and the absence of adverse events in patients with Wilms tumour receiving alisertib, targeting MYCN in selected tumours with known genomes may prove to be a fruitful strategy. To date, an objective response has been demonstrated with alisertib as a single agent and as combination therapy in atypical teratoid rhabdoid tumour and neuroblastoma, respectively 138, 139 . However, a higher response rate was not observed in patients with MYCN-amplified neuroblastoma in comparison with MYCN-non-amplified tumours 139 . In neuroblastoma cell lines, RAS inhibition results in MYCN inactivation and growth arrest 140 . The RAS superfamily (HRAS, KRAS and NRAS) contains the most mutated oncogenes in human cancer and has remained an elusive target for therapy 141 . No FDA-approved anti-RAS therapy exists, but direct inhibitors are currently undergoing preclinical testing 142 . Although mutations in RAS are rarely observed in Wilms tumour, RAS expression is associated with increased Wilms tumour size, and RAS activation has been identified in patients with the combination of variant SIX and miRNAPG 10, 143 . In mice, KRAS activation on a background of β-catenin stabilization led to metastatic renal tumours that closely resembled Wilms tumour epithelial histology 144 . Inhibition of RAS could be a potential strategy for patients with variant MYCN, miRNAPG and/or SIX1 or SIX2 tumour genomes.
Targeting epigenetic modifiers is another promising avenue, given the discovery of mutations in genes encoding subunits of the BAF chromatin remodelling complex (ARID1A, SMARCA4 and ACTB) and transcriptional co-repressors (BCOR and BCORL1). Histone deacetylases (HDACs) are epigenetic regulators that interact with the aforementioned proteins to regulate gene expression 111, 116 . Transient response to the HDAC inhibitor vorinostat was demonstrated in a child with refractory anaplastic embryonal rhabdomyosarcoma harbouring mutations in BCOR and ARID1A 145 . HDAC1 and HDAC2 maintain the renal progenitor pool, with deletion resulting in downregulation of key progenitor genes that are mutated in Wilms tumour (SIX2 and WT1) 146 . Thus, HDAC inhibitors could provide a way to target the fetal renal transcriptome. As SIX2 has been shown to drive tumour progression and metastasis in a range of adult solid tumours, inhibiting this axis warrants exploration. Further potential avenues include targeting other Wilms tumour cancer genes with critical roles in nephrogenesis, renal progenitor genes not known to be mutated in Wilms tumour and/or genes that are globally specific to the fetal nephron 68 . Another potential target is TP53, given the prevalence of TP53 mutants in anaplastic and non-anaplastic fatal Wilms tumours 54 . Currently, no trials are evaluating the efficacy of targeting TP53 in childhood cancers. However, ongoing early phase trials in adults are testing 64, 148 . A phase II trial of lorvotuzumab mertansine for patients with various paediatric solid tumours including relapsed or refractory Wilms tumour is underway 149 .
Targeting NCAM1
+ cells, using a nanosized conjugate of paclitaxel bound to polymer, inhibited tumour growth in blastema-predominant Wilms tumour xenografts without causing toxicity 150 .
In the past decade, only around 19% of children with relapse or refractory Wilms tumour were recruited to early phase trials 137 . Moreover, the outcomes of patients with relapsed or refractory Wilms tumour who were enrolled in previous trials of targeted therapy were dismal 137 . COG is aiming to address this problem by matching biological agents to actionable mutations through its MATCH (Molecular Analysis for Therapeutic Choice) initiative 151 . We should not be discouraged by previous disappointing results. Instead, the focus should be on improving access to early phase trials and personalizing recruitment through knowledge of the tumour genomes of individual patients. Further elucidating the genetic basis of Wilms tumour through large-scale studies of diverse subgroups could facilitate the identification of additional targets. International collaboration and furthering dialogue between child and adult oncology research are necessary to determine which agents to prioritize.
conclusions
The diverse genetic landscape of Wilms tumour is now beginning to be deciphered. In addition to classical genetic changes involving WT1, the IGF2 locus, the WNT pathway, MYCN and TP53, several additional cancer genes that harbour likely driver mutations in Wilms tumour have been identified. These genes include epigenetic remodellers (SMARCA4 and ARID1A), miRNAPGs and the transcription factors SIX1 and SIX2. The identification of recurrent coding mutations in DROSHA, SIX1 and SIX2 in Wilms tumour but not in other cancers suggests that these are Wilms tumour-specific genes. However, the precise role of these genes in tumorigenesis, as well as the mechanistic basis of the female bias that is seen with DGCR8 mutations, is poorly understood 10, 11 . Gene expression studies and single-cell transcriptomes that map Wilms tumour cells to stages of fetal renal development support the hypothesis that Wilms tumours arise from stalled nephrogenesis. Targeting nephrogenesis remains an unexplored avenue that may translate into novel treatment for this disease.
Of note, many of the newly discovered genes are involved in transcriptional elongation (MLLT1, CREBBP, EP300, CTR9, MAP3K4 and BRD7) 12 .
www.nature.com/nrneph Among these genes, those that have low variant allele frequencies and are infrequently mutated in Wilms tumour are likely to have a role at later stages in tumour development and are not necessarily implicated in nephrogenesis. Functional studies and the use of model systems, including renal organoids, may well further elucidate the mechanisms of tumorigenesis in the next few years. A more complete understanding of the genetic changes that drive Wilms tumorigenesis and progression has enabled the identification of potentially actionable mutations. Whether these discoveries will lead to improved survival for children with refractory, relapsed or high-risk disease remains to be seen. Knowledge of the biological heterogeneity of Wilms tumour continues to drive refinements in risk stratification through the introduction of molecular biomarkers. The next SIOP study aims to validate the clinical utility of several of these promising candidates including 1q gain 25 . Despite the discovery of ~40 Wilms tumour genes, the candidate genes driving oncogenesis in tumours with gain of 1q remain unknown. The outstanding objective remains to salvage the proportion of patients with relapsed or refractory Wilms tumour while, at the other end of the spectrum, identifying children with excellent prognosis in whom omission of therapy is a viable option. Further elucidating the underlying genetic landscape will hopefully make personalized therapy the standard of care for every child with Wilms tumour.
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